Novel Cytochrome P450 Reaction Phenotyping for Low-Clearance Compounds Using the Hepatocyte Relay Method
Authors:
Open Access
- 1 March 2016
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 44 (3) , 460-465
Abstract
A novel cytochrome P450 (P450) reaction phenotyping method for low-clearance compounds has been developed for eight P450 enzymes (CYP1A2, 2B6, 2D6, 2C8, 2C9, 2C19, 3A, and 3A4) and pan-cytochrome using the hepatocyte relay approach. Selective mechanism-based inhibitors were used to inactivate the individual P450 enzymes during preincubation, and inactivators were removed from the incubation before adding substrates to minimize reversible inhibition and maximize inhibitor specificity. The inhibitors were quite selective for specific P450 isoforms using the following inhibitor concentrations and preincubation times: furafylline (1 µM, 15 minutes) for CYP1A2, phencyclidine (20 µM, 15 minutes) for 2B6, paroxetine (1.8 µM, 15 minutes) for CYP2D6, gemfibrozil glucuronide (100 µM, 30 minutes) for 2C8, tienilic acid (15 µM, 30 minutes) for 2C9, esomeprazole (8 µM, 15 minutes) for 2C19, troleandomycin (25 µM, 15 minutes) for 3A4/5, CYP3cide (2 µM, 15 minutes) for 3A4, and 1-aminobenzotriazole (1 mM, 30 minutes) supplemented with tienilic acid (15 µM, 30 minutes) for pan-cytochrome. The inhibitors were successfully applied to the hepatocyte relay method in a 48-well format for P450 reaction phenotyping of low-clearance compounds. This novel method provides a new approach for determining the fraction metabolized of low-turnover compounds that are otherwise challenging with the traditional methods, such as chemical inhibitors with human liver microsomes and hepatocytes or human recombinant P450 enzymes.Keywords
This publication has 31 references indexed in Scilit:
- Addressing the Challenges of Low Clearance in Drug ResearchThe AAPS Journal, 2015
- In Vitro–In Vivo Correlation for Low-Clearance Compounds Using Hepatocyte Relay MethodDrug Metabolism and Disposition, 2013
- Utility of In Vitro Systems and Preclinical Data for the Prediction of Human Intestinal First-Pass Metabolism during Drug Discovery and Preclinical DevelopmentDrug Metabolism and Disposition, 2013
- A Novel Relay Method for Determining Low-Clearance ValuesDrug Metabolism and Disposition, 2012
- Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures andin silicomodelingDrug Metabolism Reviews, 2012
- Utility of Intersystem Extrapolation Factors in Early Reaction Phenotyping and the Quantitative Extrapolation of Human Liver Microsomal Intrinsic Clearance Using Recombinant Cytochromes P450Drug Metabolism and Disposition, 2011
- Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stageXenobiotica, 2006
- Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitroBritish Journal of Clinical Pharmacology, 2004
- Incidence of Adverse Drug Reactions in Hospitalized PatientsJAMA, 1998
- Diazepam metabolism by human liver microsomes is mediated by both S‐ mephenytoin hydroxylase and CYP3A isoforms.British Journal of Clinical Pharmacology, 1994